The Immunogenicity and Safety of the Live-attenuated SA 14-14-2 Japanese Encephalitis Vaccine Given with a Two-dose Primary Schedule in Children
Open Access
- 1 January 2015
- journal article
- clinical trial
- Published by XMLink in Journal of Korean Medical Science
- Vol. 30 (5) , 612-616
Abstract
Kwon HJ, et al. J Korean Med Sci. 2015 May;30(5):612-616. https://doi.org/10.3346/jkms.2015.30.5.612Keywords
Funding Information
- Korea Food & Drug Administration (08122-vaccine assessment-337)
This publication has 27 references indexed in Scilit:
- Encephalitis temporally associated with live attenuated Japanese encephalitis vaccine: four case reportsBMC Infectious Diseases, 2011
- Japanese Encephalitis: New Options for Active ImmunizationClinical Infectious Diseases, 2010
- IC51 Japanese Encephalitis vaccineExpert Opinion on Biological Therapy, 2009
- Comparison of the immunogenicity and safety of measles vaccine administered alone or with live, attenuated Japanese encephalitis SA 14-14-2 vaccine in Philippine infantsVaccine, 2008
- Vaccines for preventing Japanese encephalitisCochrane Database of Systematic Reviews, 2007
- Report on a WHO consultation on immunological endpoints for evaluation of new Japanese encephalitis vaccines, WHO, Geneva, 2–3 September, 2004Vaccine, 2005
- New initiatives for the control of Japanese encephalitis by vaccination:Vaccine, 2000
- Immunogenicity of Live Attenuated SA14–14–2 Japanese Encephalitis Vaccine—A Comparison of 1–and 3‐Month Immunization SchedulesThe Journal of Infectious Diseases, 1998
- Japanese Encephalitis Vaccine in TravellersDrug Safety, 1997
- Protection against Japanese Encephalitis by Inactivated VaccinesNew England Journal of Medicine, 1988